35.07

2.47% -0.89

Pharvaris Nv (PHVS)

Overview News Price History Discussions Forecast

Pharvaris Nv stock is traded at $35.07, with a volume of 639.26K. It is down -2.47% in the last 24 hours and up +11.30% over the past month. Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Previous Close:

$35.96

Open:

$35.79

24h Volume:

639.26K

Relative Volume:

1.57

Market Cap:

$2.45B

Revenue:

Net Income/Loss:

$-195.21M

P/E Ratio:

-11.04

EPS:

-3.1763

Net Cash Flow:

$-176.19M

1W Performance:

+3.57%

1M Performance:

+11.30%

6M Performance:

+35.46%

1Y Performance:

+76.85%

1-Day Range:

$33.97

$36.25

1-Week Range:

$33.00

$36.60

52-Week Range:

$19.12

$36.60

Pharvaris Nv Stock (PHVS) Company Profile

Name

Pharvaris Nv

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

Address

Employee

129

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

PHVS's Discussions on Twitter

Compare PHVS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHVS Pharvaris Nv	35.07	2.45B	0	-195.21M	-176.19M	-3.1763
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Wolfe Research	Outperform
Mar-09-26	Initiated	RBC Capital Mkts	Outperform
Oct-15-25	Initiated	H.C. Wainwright	Buy
Oct-09-25	Upgrade	BofA Securities	Underperform → Neutral
Jun-11-25	Initiated	Guggenheim	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Sep-25-23	Initiated	Wedbush	Outperform
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-05-22	Initiated	Bryan Garnier	Buy
Sep-13-22	Resumed	JMP Securities	Mkt Outperform
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform
May-25-22	Initiated	JMP Securities	Mkt Outperform
Mar-02-21	Initiated	BofA Securities	Neutral
Mar-02-21	Initiated	Morgan Stanley	Overweight
Mar-02-21	Initiated	Oppenheimer	Outperform
Mar-02-21	Initiated	SVB Leerink	Outperform

View All

Pharvaris Nv Stock (PHVS) Latest News

Jul 09, 2026

(PHVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jul 09, 2026

Jul 06, 2026

FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks - Contemporary Pediatrics

Jul 06, 2026

Pharvaris Insider Sold Shares Worth $1,331,496, According to a Recent SEC Filing - marketscreener.com

Jul 02, 2026

Pharvaris Insider Sold Shares Worth $2,695,452, According to a Recent SEC Filing - marketscreener.com

Jul 02, 2026

Jul 01, 2026

Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells 37,600 Shares of Pharvaris NV (PHVS) - GuruFocus

Jul 01, 2026

Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan - Stock Titan

Jul 01, 2026

Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares - Stock Titan

Jul 01, 2026

Jun 30, 2026

PHVS (NASDAQ) insiders executed multiple 10b5-1 sales in 2026 - Stock Titan

Jun 30, 2026

PHVS insiders (PHVS) list option exercise and multiple 10b5-1 sales in June 2026 - Stock Titan

Jun 30, 2026

Form 144: Hans H. Schikan 10b5-1 sales listed for PHVS (PHVS) - Stock Titan

Jun 30, 2026

Jun 29, 2026

Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells Shares of Pharvaris NV (PHVS) - GuruFocus

Jun 29, 2026

Form 144 Pharvaris N.V. For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Pharvaris (PHVS) exec’s 10b5-1 option exercise and 4,600-share sale - Stock Titan

Jun 29, 2026

Pharvaris (PHVS) director’s 2,400-share Rule 10b5-1 stock sale detailed - Stock Titan

Jun 29, 2026

Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan - Stock Titan

Jun 29, 2026

PHVS (NASDAQ: PHVS) 10b5-1 sales logged; Form 144 for 6,888 shares - Stock Titan

Jun 29, 2026

PHVS holders execute multiple 10b5-1 sales (NASDAQ: PHVS) - Stock Titan

Jun 29, 2026

8,300-share option exercise; multiple 10b5-1 sales reported (PHVS) - Stock Titan

Jun 29, 2026

Price to book forward of Pharvaris N.V. – GETTEX:9EN - TradingView

Jun 29, 2026

Jun 28, 2026

Liquidity Mapping Around (PHVS) Price Events - Stock Traders Daily

Jun 28, 2026

PHVS Gains 2.13% as Biotech Sentiment Brightens – Key Levels to WatchValue Factor - dars.gov.et

Jun 28, 2026

Jun 27, 2026

Price to book forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView

Jun 27, 2026

Enterprise value to revenue forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView

Jun 27, 2026

Pharvaris N.V. Actuals & Estimates (NASDAQ:PHVS) - TradingView

Jun 27, 2026

Enterprise value to revenue forward of Pharvaris N.V. – LS:A2QNWS - TradingView

Jun 27, 2026

Price to sales forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView

Jun 27, 2026

Price to book forward of Pharvaris N.V. – LS:A2QNWS - TradingView

Jun 27, 2026

Jun 26, 2026

Enterprise value to EBITDA forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView

Jun 26, 2026

Price to earnings forward of Pharvaris N.V. – LS:A2QNWS - TradingView

Jun 26, 2026

[144] Pharvaris N.V. SEC Filing - Stock Titan

Jun 26, 2026

Enterprise value to EBIT forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView

Jun 26, 2026

Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM - TipRanks

Jun 26, 2026

[6-K] Pharvaris N.V. Current Report (Foreign Issuer) | PHVS SEC FilingForm 6-K - Stock Titan

Jun 26, 2026

PHVS Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Pharvaris N.V. Actuals & Estimates (FWB:9EN) - TradingView

Jun 26, 2026

Jun 25, 2026

Form 144 Pharvaris N.V. For: 25 June By Investing.com - Investing.com India

Jun 25, 2026

9EN Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

PHVS (NASDAQ) director 10b5-1 sales include 29,070 shares on 04/30/2026 - Stock Titan

Jun 25, 2026

PHVS (NASDAQ: PHVS) insider plans to sell 15,000 shares after option exercise - Stock Titan

Jun 25, 2026

PHVS Maintained by Morgan Stanley -- Price Target Raised to $46. - GuruFocus

Jun 25, 2026

PHVS (NASDAQ) reports director/entity 10b5-1 sales on April 22–30, 2026 - Stock Titan

Jun 25, 2026

PHVS (NASDAQ) files Form 144: 2,300 shares tied to option exercise - Stock Titan

Jun 25, 2026

Jun 23, 2026

Pharvaris (PHVS) CMO sells 300 shares in scheduled 10b5-1 trade - Stock Titan

Jun 23, 2026

Jun 19, 2026

Pharvaris (PHVS) Is Up 6.0% After Strong Phase 3 Oral HAE Data With Novel Endpoint Introduction - Sahm

Jun 19, 2026

PHVS Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Clinical ProgressRevenue Miss Report - dars.gov.et

Jun 19, 2026

Jun 18, 2026

PHVS reports 10b5-1 sales and option exercise (PHVS) - Stock Titan

Jun 18, 2026